Hemophilia Global Market Report 2024

“Hemophilia Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemophilia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemophilia? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The hemophilia market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
• 2) By Treatment: Replacement Therapy; Hemostatic Agents; Desmopressin; Gene Therapy; Other Treatments
• 3) By End-User: Hospitals; Clinics; Home Care Settings; Other End-Users
• Companies Mentioned: Kedrion S.p.A.; Chugai Pharmaceutical Co. Ltd.; Pfizer Inc.; F. Hoffmann-La Roche AG; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Hemophilia is a rare genetic disorder that affects the body's ability to clot blood properly and generally occurs when a person gets injured and starts bleeding. Hemophilia treatment treats Hemophilia disease through various medical interventions and strategies to manage and address the bleeding tendencies associated with hemophilia.

The main types of hemophilia are hemophilia A, hemophilia B, hemophilia C and others. Hemophilia A refers to a genetic disorder characterized by a deficiency of a protein called clotting factor VIII (factor 8). The various treatments include replacement therapy, hemostatic agents, desmopressin, gene therapy and others. These are used by various end-users such as hospitals, clinics, home care settings and others.

The hemophilia market research report is one of a series of new reports from The Business Research Company that provides hemophilia market statistics, including hemophilia industry global market size, regional shares, competitors with a hemophilia market share, detailed hemophilia market segments, market trends and opportunities and any further data you may need to thrive in the hemophilia industry. This hemophilia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemophilia market size has grown strongly in recent years. It will grow from $12.59 billion in 2023 to $13.83 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to government initiatives, increased number of hemophilic patients, rising diagnostic screening, increasing awareness about hemophilia treatments.

The hemophilia market size is expected to see strong growth in the next few years. It will grow to $19.4 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to rising research and development hemophilias, rising diagnostic screening, incremental healthcare spending, global access to treatment. Major trends in the forecast period include new drug launches and approvals, escalation in novel drug development, research and clinical trials, digital health solutions, advancements in treatment options.

The growth of the hemophilia market is expected to be primarily driven by the rising incidence of genetic abnormalities. Genetic abnormalities, also known as genetic mutations or genetic disorders, refer to alterations in an individual's DNA sequence that can lead to various health conditions and physical traits. Hemophilia treatment aims to mitigate or control bleeding episodes, reduce complications, and enhance the quality of life for individuals with genetic abnormalities. For instance, in June 2023, Gene People, a UK-based registered charity organization supporting individuals with genetic conditions, reported that one in every 25 children in the UK had a genetic disorder, affecting approximately 30,000 newborns and young children in the country, as well as more than 2.4 million children and adults annually. Consequently, the increasing occurrence of genetic abnormalities is a driving force behind the growth of the hemophilia market.

The growth of the hemophilia market is expected to be driven by increasing investment efforts in hemophilia care. These efforts encompass the allocation of financial resources, research and development initiatives, and healthcare infrastructure enhancements, all aimed at advancing the treatment, management, and overall well-being of individuals with hemophilia. By improving access to hemophilia treatment, particularly in developing regions, these initiatives and partnerships work to expand the patient pool and market size. For example, in September 2022, the National Hemophilia Foundation (NHF), a nonprofit organization based in the United States, introduced Pathway to Cures (P2C), an innovative venture philanthropy investment fund with an initial funding of $3.5 million. P2C is dedicated to achieving substantial and transformative advancements in the field of inheritable blood disorders, capitalizing on its team's expertise in blood disorder research and leveraging NHF's valuable connections with scientific research institutions and clinical experts. Therefore, the increasing investment efforts in hemophilia care are expected to be a driving force behind the growth of the hemophilia market.

The hemophilia market's growth in the forecast period may be constrained due to the high cost of treatment, which can limit access to care. The substantial expenses associated with clotting factor concentrates pose financial challenges for both patients and healthcare systems. The elevated cost of treatment imposes significant limitations on the management and care of hemophilia patients. For example, as reported in the 2022 Costs of Caring publication by the American Hospital Association, hospital prices increased by 2.1% over the year leading up to February 2022. Thus, the hindrance to market growth is primarily attributed to the high treatment costs.

Major companies operating in the hemophilia market are focusing on the development of innovative drugs, such as ALTUVIIIO, to maintain their competitive position. For example, in February 2023, Sanofi S.A., a France-based pharmaceutical and healthcare company, introduced ALTUVIIIO for the treatment of hemophilia. This medication received approval from the US-based government agency, the Food and Drug Administration (FDA). ALTUVIIIO offers the unique benefit of once-weekly dosing, providing regular to near-normal factor activity levels (above 40%) for most of the week and significantly reducing bleeding compared to previous factor VIII prophylaxis.

In February 2023, Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical company specializing in hemophilia drugs, acquired Nimbus Therapeutics LLC for a sum of $4 billion. This strategic acquisition strengthens Takeda's late-stage pipeline and expands its portfolio, potentially broadening its impact on patients across multiple medical conditions. Nimbus Therapeutics LLC, a US-based pharmaceutical company, is engaged in the development and manufacturing of drugs for hemophilia.

Major players in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Precision BioLogic Inc., Dimension Therapeutics, Chameleon Biosciences, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB .

North America was the largest region in the hemophilia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hemophilia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hemophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The hemophilia market consists of revenues earned by entities by providing physical therapy, hemophilia centers (HTCs) and prophylactic care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemophilia market consists of sales of hemophilia drugs and medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.